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Abstract
Recent technological advances in radiation therapy have allowed for greater
accuracy in planning and treatment delivery. The development of
hypofractionated radiation treatment regimens is an example, and has the
potential to decrease the cost per episode of care, relative to conventional
treatments. Our aim was to analyse published literature on the cost-
effectiveness and budgetary implications of hypofractionated radiation therapy.
As such, this article will quantify the projected health care cost savings and
address the optimal means of treatment delivery, associated patient outcomes,
and implications arising from an increased use of hypofractionated regimens.
Background
The financial stability of a public health care system is at
the mercy of a number of conflicting factors. A
dichotomy exists between those who view health care as
expenditure (payers), and those who profit from it
(providers). Similarly, the pressures of supply and
demand challenge a dynamic health care system to be
both proactive and responsive to change.1 Expenditure
and cost-control strategies must accommodate, and not
exacerbate this tension. A multidimensional approach to
cost-containment is recommended to support an ever-
changing industry.
Cost-containment strategies vary by country and
geographic region. Stabile et al. 2 compared the various
means of addressing rising health care costs in four high-
income nations – France, Germany, England and Canada;
all of which are heavily reliant on public funding. Whilst
significant differences exist in the organisational models
of these health care systems, the cost-containment
strategies were comparable across nations. Three major
approaches emerged; budget shifting, budget setting and
direct/indirect controls. Budget shifting can simply be
explained as limiting/omitting benefits, introducing user
co-payment and/or moving costs across different
government platforms. In contrast, budget setting
involves capping overall health care funding and/or
adjusting the means of provider payment to activity-
based remuneration. The third means of cost-
containment, most influential at provider-level, is by
imposing direct or indirect controls. This includes greater
Government control over price, infrastructure, technology
and clinical practice guidelines. This in turn drives
providers to seek more efficient and innovative means of
achieving outcomes.
The Australian context
In the 2014–15 financial year, the Australian Government
invested $161.6 billion into the Australian health care
system.3 This represents an increase of 2.8% over the
previous financial year (2013–14 – $155 billion) and is
indicative of the upward trend in health care spending
(with an average annual growth of 4.6% over the last
decade). In addition to the contributing factors of an
ageing population and a developing health workforce,
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technological advancement accounts for a considerable
cost-driver within Australia. The investment in health
care must be carefully balanced so as to support the
expansion of service provision, but not succumb to
financial penalty. Duckett & Willcox1 suggest that the
control and/or reduction in health care cost has been
integral to policy makers within the Australian
Government over recent decades. Though this issue is not
new, it continues to evolve with a health care system that
grows in complexity.
In 2011, cancer accounted for the largest burden of
disease amongst Australians.4 Conventional cancer
treatment modalities include surgery, chemotherapy and
radiation therapy. Radiation therapy is defined as the use
of ionising radiation directed at a localised treatment site
to kill and/or damage cancer cells.4 It may be used in
conjunction with the aforementioned modalities, or as
the primary treatment. Whilst there are a number of
methods available for the delivery of radiation therapy,
the most common application is external-beam radiation
therapy; by means of a linear accelerator (LINAC)
machine.
Investment in radiation therapy occupies a substantial
proportion of health expenditure. The Australian
Government Department of Health 5 reports that in
2014–15, radiation therapy funding exceeded $411
million, of which $343 million constituted service delivery
by Medicare benefits and a further $68 million comprised
service improvement/expansion via the Radiation
Oncology Health Programs Grant (ROHPG). Unlike the
modest increase in overall health expenditure (2.8%),
radiation therapy saw a net increase of 13.5% from the
previous financial year. From 1988 to 2015, the number
of LINACs installed nationally has increased considerably
from 46 to 197 with a simultaneous rise in treatment
facilities from 18 to 82 within the same period.5 The
growing trend to establish more treatment facilities in
regional and remote areas has enhanced access to
radiation therapy services, but has come at a substantial
cost. To offset capital gain investment in expanding
service delivery, a number of cost-containment strategies
have been employed to increase value in service
provision. These strategies include technological
innovation, bolstered efficiency, public-private partnership
and service delivery targets.
A radiation therapy course is prescribed by a Radiation
Oncologist and can constitute between 1 and 39 fractions
(treatment sessions). In Australia, approximately 1.9
million fractions are delivered each year.5 The Australian
Government provides significant funding, such that 80%
of all services are charged at the Medicare Benefits
Scheme schedule fee or less, thus most patients incur no
(or very little) out-of-pocket expenses. Whilst 40% of
patients elect for private treatment, Medicare provides
part-payment, with patients incurring the gap. 2014 fees
for an average three-field radiation therapy treatment
across 20 fractions was $11,433. Of this amount, the
Medicare rebate was $8784, with patients incurring the
$2649 gap.
The major influencing factor in the escalation of
radiation therapy course costs is indeed the fractionation
schedule. A current clinical trial of hypofractionated
prostate radiation therapy (PROFIT) has gained
considerable media attention due to the strong likelihood
that a shorter alternative to standard cancer treatment
can elicit comparable outcomes for patients, at a
considerably lower cost.6
Hypofractionation is a means of reducing the overall
treatment course duration by delivering larger doses of
radiation per fraction. Hegemann et al. 7 report that the
first published studies on hypofractionated radiation
therapy were conducted in Australia, Canada and the
United Kingdom in the 1990s. The long distances
travelled to access radiation therapy and the similarities
of health care reimbursement across these three nations
have fuelled an interest in more efficient means of
treatment delivery without loss of quality and associated
patient outcomes. The expansion of technology and
innovation has fostered and reignited the use of
hypofractionation as a safe and effective means of
escalating dose to improve tumour kill at the treatment
site. As such, variations of moderate (radical breast/
prostate) and extreme (palliative Stereotactic Body
Radiation Therapy or SBRT) hypofractionation are fast
becoming established means of treatment delivery.
Although hypofractionation presents a possible means of
reducing financial costs, one must consider the additional
resources and associated patient outcomes.
Methodology
A literature review of PubMed, Proquest and the
Cochrane Library was conducted in December 2017,
using the search terms ‘hypofractionated’, ‘radiation’ and
‘cost’ (see Fig. 1). The combined search yielded a total of
one-hundred-and-eighty articles. In accordance with
PRISMA guidelines,8 84 articles were removed as
duplicates, leaving 96 articles for consideration. A further
26 articles were removed with limitations placed on
English language, human studies, full-text and published
within the past 10 years. The limitation placed on the
past 10 years was selected so as to reflect the modern
application of IMRT, VMAT and SBRT technologies that
are cognizant within the current financial climate. Thus,
seventy articles were assessed for eligibility; considerate of
LINAC-based delivery and relevance to cost-analysis.
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Eligibility criteria removed a total of 46 articles –
seventeen by evaluation of title and a further 29 removed
by abstract. Twenty-four articles were included for
qualitative and quantitative analysis. Although the
included articles varied in tumour stream and
international context (see Table 1), commonalities existed
in the discussion of health care cost reduction, optimal
treatment delivery, patient costs and future
considerations. These four emergent themes will be
discussed below.
Discussion
Health care cost reduction
Current research suggests that the number of US patients
requiring radiation therapy is due to rise from 470,000 in
2010 to 575,000 by 2020.9 This growth in patient
numbers needs to be met with more cost-effective means
of treatment delivery. It is important to acknowledge that
radiation therapy is largely considered cost-effective by
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Figure 1. Literature search – screening and eligibility.
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Table 1. Overview of literature reviewed.
Reference
Tumour
stream
Publication
type Recruitment figure Key study outcome
Konski, AA,9 University of
Pennsylvania, USA (2017)
Multiple Review N/A Increased use of hypofractionation may increase
patient value by reducing direct/indirect medical
and productivity costs.
Laine, AM et al.,10 University of
Texas Southwestern Medical
Center, USA (2016)
Multiple Review N/A Hypofractionation provides an efficacious, cost-
effective, efficient and convenient alternative to
standard fractionation for a limited range of
tumours.
Lievens, Y,11 University Hospital
Gustuisberg, Belgium (2010)
Breast Review N/A Despite acute gains to clinical outcomes and cost,
long-term data must assess the post-treatment
management costs attributed with increased
hypofractionation.
Aneja, S et al.,12 Yale School of
Medicine, USA (2012)
Prostate Review N/A Hypofractionated prostate radiotherapy promises
resource-efficient and comparable patient
outcomes to standard fractionation.
Kang, JJ et al.,13 David Geffen
School of Medicine UCLA, USA
(2015)
Bladder Retrospective
Analysis
26 patients (M/F), T2–4 N0
–2M0 urothelial cancer
Hypofractionated partial bladder radiotherapy
offers comparable local control and survival, with
reduced cost/time.
Voong, KR,14 MD Anderson
Cancer Centre, USA (2015)
Prostate Conference
Abstract
N/A Hypofractionated prostate radiotherapy is seen to
reduce costs, including the management of late
radiation toxicities.
Greenup, RA et al.,16
Massachusetts General Hospital,
USA (2017)
Breast Retrospective
Analysis
43,247 patients (F), T1–
T2 N0 invasive breast
cancer
Hypofractionated breast radiotherapy offers high-
value care, with a potential to reduce overall
treatment costs by 39%.
Dwyer, P et al.,17 Princess
Alexandra Hospital, Australia
(2010)
Breast Retrospective
Analysis
279 patients (F), T1–T2 N0
invasive breast cancer
Hypofractionation could reduce costs by 24%;
allowing for an additional 14 patients to be
treated at the department each month.
Mortimer, JW et al.,18 University
of New South Wales, Australia
(2016)
Breast Retrospective
Analysis
196 patients (F). T1–T4 N0
–3 invasive breast cancer
Hypofractionated breast cancer radiotherapy could
reduce costs by 29.3% (22.1–32.0%).
Barry et al.,19 University of
Louisville, USA (2015)
Breast Cost-effective
Analysis
N/A Conventional breast radiotherapy is financially
burdensome in weeks 5–7, with no clear benefit
to quality of care and patient outcomes. Once-
weekly hypofractionation could reduce costs by
65%.
Khan, AJ et al.,20 Robert Wood
Johnson Medical School/Cancer
Institute of New Jersey, USA
(2016)
Breast Retrospective
Analysis
100 patients (F), T1–T4 N0
–3 invasive breast cancer
Hypofractionation not only provides efficiency and
cost saving, but translates to improved access to
care in developing economies.
Konski, AA et al.,21 University of
Pennsylvania, USA (2016)
Multiple Cost-effective
Analysis
N/A Increasing the rate of hypofractionation to 40%
would reduce annual technical revenue by
$540,661 and patient workflow by five patients
(1–1.5 h) per day.
Muller-Riemenschneider, FM
et al.,22 Charite-
Universitatsmedizin, Germany
(2009)
Cranial Review N/A Increased use of hypofractionated techniques such
as SRS must consider the economic implications
of adaptive/dedicated equipment utilisation.
Deshmukh, AA et al.,23 University
of Florida, USA (2017)
Breast Cost-effective
Analysis
N/A Hypofractionated breast radiotherapy offers the
most cost-effective option overall, as compared
with conventional fractionation or brachytherapy
(IORT).
Ojerholm, E et al.,24 University of
Pennsylvania, USA (2017)
Breast Editorial N/A Increased use of hypofractionated breast
radiotherapy could provide equivalent patient
outcomes, improve convenience and save $100
million each year.
(Continued)
ª 2018 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of
Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology
151
D. Hunter et al. Cost-Containment in Hypofractionated RT
means of Incremental Cost-Effectiveness Ratio (ICER)
analyses; certainly in comparison with systemic
treatments.10 However, within the period of 1996 to 2016
there has been a considerable increase in cost-effective
analysis publications within the context of radiation therapy
practice. Amongst the various components that are thought
to contribute to cost-effectiveness, changes to fractionation
have accounted for the second largest body of work in this
field. Cost-calculation models have demonstrated that daily
operating expenditures outweigh capital machine costs in
the planning and delivery of radiation therapy treatment.11
As such, Aneja et al.12 suggests that radiation therapy costs
are largely a product of time; given by the duration of each
fraction multiplied by the total number of fractions.
Therefore, hypofractionation has the potential to reduce the
burden of rising health care costs in the area of radiation
therapy.11,13 It is estimated that the contribution of direct
planning and treatment delivery costs are 20% and 80%
respectively.13 The use of hypofractionation is most
commonly discussed in prostate and breast applications, of
which constitute the two largest patient cohorts.4
Prostate cancer accounts for the longest course of
radiation therapy by comparison with other anatomical
sites, due to the radioresistant nature of prostatic
tissue. International standards suggest that prostate
radiation therapy is given as 75.6–81.0 Gy in 1.8–
2.0 Gy per fraction over 7–9 weeks.12,14 In Australia,
typical doses are either 74 Gy (in 37 fractions) or
78 Gy (in 39 fractions) in the setting of post-
prostatectomy or intact prostate respectively. In either
case, the treatment is rather cumbersome and very
expensive. US data suggests that a typical course of
conventional prostate radiation therapy can cost in the
vicinity of $30,241–$37,125 accounting for PSA testing,
imaging, symptom management and consultation
fees.12,14 In contrast, a moderate hypofractionation
schedule of 30 fractions could see a saving of
approximately $7000 per patient, with the course cost
weighing in at $22,957.14 With an estimated 180,000
new diagnoses of prostate cancer in the United States
alone each year, this could translate to significant
health care cost savings.12
Table 1. Continued.
Reference
Tumour
stream
Publication
type Recruitment figure Key study outcome
Sharieff, W et al.,25 Juravinski
Cancer Centre, Canada (2014)
Prostate Cost-effective
Analysis
5000 patients (M), T < 2a,
Gleason score <6, PSA
<10 ng/mL prostate
cancer
Providing equivalent efficacy and safety of SBRT
delivery methods, arc-based delivery offers the
most cost-effective method.
Zemplenyi, AT et al.,26 University
of Pecs, Hungary (2016)
Prostate Cost-effective
Analysis
N/A Hypofractionated IMRT for prostate cancer offers
the most cost-effective means of delivery, as
compared with standard fractionated 3D-CRT or
IMRT.
Lievens, Y et al.,40 Ghen University
Hospital, Belgium (2015)
Lung Cost-effective
Analysis
Financial data from 10
participating centres.
Time-based reimbursement may provide a means
of supporting the introduction of advanced
radiotherapy techniques.
Min, C et al.,27 New York
University, USA (2014)
Breast Prospective
Randomised
Trial
84 patients (F), Tis-T2, N0–
Nx invasive breast cancer
At 3-year follow-up, hypofractionated breast
radiotherapy appears to provide a promising
option – particularly for elderly, non-surgical
candidates.
Bekelman, JE et al.,28 University of
Pennsylvania, USA (2014)
Breast Retrospective
Analysis
Financial data from 14
commercial health care
plans.
Though the rate of use has increased, a mere 21.2
–34.5% of eligible patients receive
hypofractionated breast radiotherapy.
Ohri, N & Haffty, BG,30 Rutgers
Cancer Institute of New Jersey,
USA (2018)
Breast Review N/A Hypofractionated approaches to breast cancer
(including accelerated partial breast irradiation)
offer an effective alternative for selected patients.
Voong, KR et al.,35 The John
Hopkins School of Medicine, USA
(2017)
Prostate Prospective
Randomised
Trial
204 patients (M), T1–T2,
Gleason score 6–8
Moderate hypofractionated prostate radiotherapy
offers increased value, considerate of late toxicity.
Eblan, MJ et al.,36 University of
Pennsylvania, USA (2014)
Breast Review N/A Hypofractionated breast radiotherapy offers cost
savings, increased patient throughput and
reduced waiting lists.
Konski, AA,38 Wayne State
University, USA (2012)
Prostate Commentary N/A Although hypofractionated prostate radiotherapy
offers convenience to patients, brachytherapy
provides further cost reduction.
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The Australian Medicare Benefits Schedule (MBS)
provides a clear framework for the billing of all radiation
therapy procedures, including CT/simulation, dosimetry,
image verification and daily treatment provision. MBS
item codes vary with the level of complexity of treatment
and planning processes.15 As such, the most advanced
form of treatment planning and delivery (Intensity
Modulated Radiation Therapy – IMRT), incurs the
greatest reimbursement. Thus, it is highly advantageous
for centres to implement IMRT planning, with additional
benefits to patient outcomes and centre revenue. IMRT
planning incurs a higher rate of reimbursement of CT
and dosimetry at $710.55 and $3313.85 respectively. In
contrast, conventional means of planning would be
charged at a rate of $658.60 for CT and $1120.75 for
dosimetry.
By stark contrast, the daily treatment costs are not
significantly different and there is no financial incentive
to deliver fewer treatments. Irrespective of the duration of
treatment, IMRT treatment is billed at $182.90 per
treatment, as opposed to $211.45 for a 5-field conformal
technique. In either case, a hypofractionated course
would simply suffer a considerable net loss of income.
Inclusive of equal planning costs, a proposed
hypofractionated prostate IMRT schedule (20 fractions)
would cost $7682.40, compared with $11,157.50 for
standard fractionation (39 fractions).
Breast radiation therapy has similarly been the
discussion of debate for hypofractionation in recent
history. Greenup et al. 16 suggests that breast cancer
treatment costs are higher than any other tumour stream,
with an estimated cost of $20 billion by 2020 in the
United States. Radiation therapy plays an integral part of
standard breast cancer treatment, as such, contributing
heavily to this cost burden.17 Conventional radiation
therapy courses for breast cancer are provided as 50 Gy
in 25 fractions. A growing trend to hypofractionation has
seen a number of patients receive 40 Gy in 15 fractions,
or 42.5 Gy in 16 fractions. While comparatively smaller
than the prostate hypofractionated regime, a reduction in
nine fractions has seen a reduction in cost per patient
from $13,358 to $8328 in the United States – a staggering
difference of 38%.16 Australian data has echoed a
comparable 32% cost reduction from $8272 to $5613.18
These figures consider not only the additional costs per
fraction delivered, but the associated weekly management
costs – of which are substantially burdensome beyond
week 4 of breast cancer treatment.19
Research conducted in the USA found that 57%
patients underwent treatment regimens for breast cancer
that were unnecessarily costly, accounting for a total
$420.2 million in 2011.16 Had patients been treated with
more fiscally conservative radiation therapy options, this
figure would have been reduced by $164.0 million to
$256.2 million – a net cost saving of 39%. Extrapolation
of similar Australian data suggests a comparable
reduction in expenditure for breast radiation therapy
from $31.3 million to $22.2 million – accounting for a
$9.1 million saving (29% reduction).18 Khan et al.20
suggest that these savings could be redirected, resulting in
profound additional benefits in treatment access via a
reduction in waiting times and improved service delivery
– particularly in emerging economies of the world.
Optimal treatment delivery
There is consensus in the literature to suggest a growing
trend to the use of hypofractionated regimens. The
further development and implementation of sophisticated
treatment planning systems and image verification has
allowed for improved accuracy of treatment, in turn
permitting the use of hypofractionation in a safe
manner.9 In 2010, 64% of radiation oncologists in the
United States had access to equipment sufficient for the
application of hypofractionation techniques. Research
suggests that uptake of hypofractionation across the
United States in 2011 was observed in 8% of prostate
cancer patients, 44% of inoperable lung cancer patients
and 20–35% in the setting of breast cancer.16,21 In
contrast, the uptake figures across Canadian breast cancer
patients is currently estimated at 70%; perhaps reflecting
differences in practice attributed to varying models of
health care.
Aneja et al. 12 propose that radiation therapy costs are
proportionate to the number of fractions. While there is
truth to this statement, the escalation of costs is not so
simply derived by the number of treatments, but also the
means of treatment delivery. Significant variations in
cost-per-fraction exist between moderate and extreme
hypofractionation (stereotactic body radiation therapy –
SBRT). Similarly, a range of treatment techniques can be
applied including external beam radiation therapy or
brachytherapy, resulting in a different cost per fraction.11
Variations on the delivery of external beam radiation
therapy (arc, fixed gantry and robotic) can also alter
treatment costs. Economic efficiency must also consider
both the downstream costs and access to systems –
dedicated or adaptive – to provide hypofractionated
radiation therapy.10,22–24
Prostate cancer is subject to a range of options of
conventional, moderate and extreme hypofractionation.
As such, there are currently no clear guidelines for
clinicians in implementing prostate hypofractionation.
Aneja et al. suggest this may contribute to lower rates of
uptake for prostate cancer, compared with breast and
lung cancer.12 Moderate hypofractionation aims to
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maintain tumour control and toxicity within a shorter
fractionation, while extreme hypofractionation provides a
more aggressive approach of higher dose in fewer
fractions (but is subject to uncertainty surrounding the
implementation and outcomes). Sharieff et al. 25 found
that extreme hypofractionation for prostate cancer can
reduce treatment costs by approximately 27–55%,
compared with conventional treatment. Similarly,
moderate hypofractionation accounts for a 22% decrease
in cost, as opposed to conventional treatment.26
Furthermore, arc-based delivery is considered the most
cost-effective treatment, allowing for a 21–32% reduction
in cost in comparison with equivalent applications of
robotic or fixed-gantry radiation therapy.25
Extreme hypofractionation is gaining acceptance as a
standard modality in lung cancer. However, research has
demonstrated that the treatment costs for extreme
hypofractionation are similar to conventional treatment,
whereas moderate hypofractionation is less costly.26 This
disparity is attributed to a number of factors such as
additional time (planning and daily treatment) and
resources (senior radiation oncologists, physicists, and
skilled radiation therapists). The varying costs of extreme
hypofractionation reported may also reflect local
differences in service delivery, such as departmental
experience with the use of these technologies.
Patient costs
Whilst evidence supports the cost-saving attributed with
hypofractionation, a paramount concern is, of course,
patient outcomes associated with treatment. The value of
radiation therapy is determined by patient satisfaction
and, similarly, treatment-related outcomes. It is largely
accepted that late toxicity is strongly correlated with the
dose per fraction – a key component of
hypofractionation.12 However, research suggests that the
toxicity attributed to hypofractionation is largely
comparable with that seen in conventional radiation
therapy courses.9
Hypofractionation in breast cancer is seen to provide
promising local control rates and good cosmetic
outcomes.16,27,28 Published data from the UK START
trials confirm the safety and efficacy of hypofractionated
breast radiation therapy,29 negating prior concerns of
long-term (cardiac) post-treatment management.11 The
combined START-A and START-B trials enrolled a total
of 4451 women across the UK between 1999 and 2002.
Analysis at 10-year post-treatment has confirmed no
long-term detriment with the use of hypofractionation,
but rather comparative patient outcomes for START-A,
and rather, improved rates of disease-free survival and
overall survival with the START-B hypofractionated
intervention (40 Gy in 15 fractions). Khan et al. 20
proposes that the equivalence of conventional and
hypofractionated radiation therapy for breast cancer is
now undisputed. As such, hypofractionation in breast
cancer is supported by current practice guidelines and the
Choosing Wisely initiative endorsed by the American
Society for Radiation Oncology.24,30
There is considerable evidence to support the use of
hypofractionation in the setting of lung cancer and
palliation. Extreme hypofractionated regimens for lung
cancer offer favourable outcomes with a cost-effective and
less invasive procedure than surgery and associated
hospitalisation.21 Furthermore, multiple studies across
Europe and the USA have demonstrated an equivalent
outcome in hypofractionated palliation compared with
conventional approaches – though this technique is
heavily underutilised.21,31–33
Hypofractionation in prostate cancer is subject to
debate surrounding clinical efficacy and increased bowel/
urinary toxicity. Recent literature has demonstrated a
significant increase in gastrointestinal and genitourinary
toxicity across Australian and Canadian
demographics.12,34 However, on cost alone, symptom
management represents a small part (<10%) of the
average total cost for patients who develop grade 2/3
bowel or urinary toxicity.13 In contrast, additional studies
have demonstrated that hypofractionation is effective in
the management of prostate cancer, with attributed health
gains.21,26,35
Hypofractionated radiation therapy presents patients
with a number of attractive benefits. Reduced waiting lists
and resultant increased capacity for radiation therapy
access is a striking benefit of hypofractionation.17,36
Current data predict considerable insufficiencies with
service provision to meet the demands of 52% of new
cancer diagnoses by 2022.37 Furthermore, this treatment
regimen provides a convenience to patients, with fewer
commutes to the radiation therapy centre.12,36,38 As such,
there are potential reductions in patient out-of-pocket
expenses including the cost of commuting/parking, and
income/productivity loss associated with longer treatment
courses.11,25,28,38 Further savings to care provision may be
associated with a reduced need for patient
accommodation, nursing/doctor consultations and the
State-funded Patient Assisted Transport Schemes.39
Therefore, the use of hypofractionated radiation therapy
may provide a fiscally desirable alternative not only to
conventional radiation therapy, but also to surgical
interventions such as prostatectomy or mastectomy.9
This modern approach to treatment is yet to constitute
standard of care in many centres worldwide. In the light
of ongoing uncertainty surrounding some applications of
hypofractionation, further challenges exist in gaining
154 ª 2018 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of
Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology
Cost-Containment in Hypofractionated RT D. Hunter et al.
acceptance amongst radiation oncologists, who may hold
firm beliefs on conventional treatments.21,28 Ultimately,
further research is required to quantify the value of
hypofractionation in achieving better clinical outcomes
and enhanced quality of life across a broad range of
treatment applications.9
Future considerations
The expansion of hypofractionated radiation therapy
must take into account the direct impacts on service
providers, the health workforce and advances in clinical
practice and technological development. A reduction in
Government funding for radiation therapy treatments will
result in a decline in hospital department revenue.17
Evidence suggests that a typical US radiation therapy
department could see a reduction in technical revenue by
$540,661 should hypofractionation constitute 40% of the
patient load.21 Given that lung, prostate, breast and
palliation account for a majority of sites treated with
radiation therapy, this figure is not unrealistic. In
addition to revenue loss, this hypothetical shift would see
a reduced workflow of approximately five patients (or
1.5 h) per day, unless counterbalanced by an increase in
billable treatment and planning sessions.17
With a net loss of revenue, departments will likely be
challenged to address budget shortfalls at a local level.38
With a reduction in the need to expand the fleet of linear
accelerators, equipment funding (i.e. ROHPG) could be
redirected to departments as a means of ensuring research
and development activities progress.21 Alternatively there
may be a push back from department level to evaluate the
reimbursement model in an attempt to regain a
comparable revenue stream.17,30 In the United States, there
is currently movement afoot to adjust the current fee-for-
service model to a bundle payment for care improvement
(BPCI) as part of revised Affordable Care Act (ACA).19
However, Konski et al. 21 warns that ‘what is not known is
whether the transition from standard therapy to more
technically demanding but higher-reimbursed therapy will
offset the loss of volume’ (p. e581).
Reducing revenue will likely see impacts on the
workforce.38 Research suggests that the increase in
hypofractionation will likely exacerbate a projected
oversupply of radiation oncologists from 2015 to 2025.9
Workforce reduction would likely cause significant issues
across rural and remote treatment centres, in particular.
Staff training and education would need to evolve with
the changing landscape. Konski et al. 21 argues that the
effects of hypofractionation could fuel a reduction in
student numbers across the medical radiation programs.
Reflective of the current climate, the 2014 American
Society of Radiologic Technologists enrolment report
indicated that 18.8% of all medical radiation programs
will likely decrease student enrolment, and similarly, there
was an observed 1.6% decrease (from 2013 to 2014) in
the success of students gaining employment 6-month
post-graduation. One might suggest that further
reduction in the workforce will only fuel this decline.
Conclusion
Hypofractionation provides a feasible means of reducing
health expenditure in the setting of radiation therapy. A
large number of radiation therapy centres across Australia
now have the requisite equipment and staff experienced
in this mode of treatment delivery, aiding transition and
implementation at a department level. Evidence supports
the potential for significant cost-saving across a health
care sector that is projected to increase and impose a
significant burden on the overall Australian health care
budget.
Whilst hypofractionated radiation therapy could
constitute an effective cost-containment strategy at
Government level, one must consider the wider
implications. Further research and cost-effectiveness
analyses are required to ascertain governance around the
best method of delivery. A number of techniques are
employed worldwide, with varying success. The best value
in the context of the Australian Medicare Benefits
Scheme must be analysed and considered with projected
workforce growth and patient demand. Patient outcomes
must be paramount to this research, such that treatment
efficacy is maintained and/or improved. Additional costs
including long-term side-effect management must be
considered, so as not to impart further burden on
another health care sector.
The growth of the profession must also be considered.
Funding must continue to drive innovation and
development in a field that is highly dependent on
progressive technology. The impact of increased
hypofractionated delivery must coincide with reducing
the strain of waiting lists and improved access to services.
Similarly, the intake of students into educational
programs must align with the projected clinical services
so as to avoid over-supply and unemployment within this
health care sector.
Ultimately, hypofractionation presents a promising
approach to cost-containment in radiation therapy and
the wider health care budget, but the issues of
implementation and potential workforce repercussions
must be addressed and planned for.
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